statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CMPX stock results show that Compass Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023

Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line...

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Compass Therapeutics announces publication of CTX-8371 preclinical data

CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface...

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

Foresite Capital Management V LLC cut its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX  Free Report) by 5.8% in the third quarter, according to its most recent Form 13F filing with the...

Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Foresite Capital Management V LLC

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Compass Therapeutics, Inc. (NASDAQ:CMPX  Free Report)  Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Compass Therapeutics in...

Research Analysts Offer Predictions for Compass Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:CMPX)

Key Insights Institutions' substantial holdings in Compass Therapeutics implies that they have significant influence...

Great week for Compass Therapeutics, Inc. (NASDAQ:CMPX) institutional investors after losing 65% over the previous year

Compass Therapeutics provides updates regarding ongoing projects...

Compass Therapeutics provides updates regarding ongoing projects

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Volume	16,927.00
52-Wk High	$3.62
52-Wk Low	$1.15

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.11	--	--	N/A
Q4'23	-$0.09	-$0.11	-26.92%	MISSED
Q3'23	-$0.11	-$0.08	25.33%	BEAT
Q2'23	-$0.08	-$0.09	-10.53%	MISSED
Q1'23	-$0.11	-$0.06	43.53%	BEAT

CMPX Compass Therapeutics Inc

About

Feed

News

Earnings

Fundamentals